Novo Nordisk's chairman Helge Lund and several other independent board members have indicated they will step down next month, ...

The company ended the first half of this year with €3.1 billion ($3.6 billion) in cash reserves, and is due to report its ...

GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...

Hevia and Sousa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data ...

Alex and Schnappauf explain how Vault CRM is a step-change for companies like Bayer, and discuss the benefits of being able ...

However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer that pharmaphorum spoke about with Dr Nicoletta ...

Researchers in the UK have started recruiting patients for a large-scale trial that will test a battery of Parkinson's ...

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) came out of the blocks strongly at the ESMO congress with ...

The Galleri multi-cancer early detection (MCED) test – which looks for around 50 different types – achieved a seven-fold ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...